AbbVie (ABBV) Stock Overview
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
ABBV Community Fair Values
Create NarrativeSee what 434 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$234.26 |
| 52 Week High | US$244.81 |
| 52 Week Low | US$164.39 |
| Beta | 0.33 |
| 1 Month Change | 5.04% |
| 3 Month Change | 4.41% |
| 1 Year Change | 10.77% |
| 3 Year Change | 50.86% |
| 5 Year Change | 120.77% |
| Change since IPO | 569.31% |
Recent News & Updates
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.AbbVie: Dominating Immunology While Building Oncology Upside
Feb 17Recent updates
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.AbbVie: Dominating Immunology While Building Oncology Upside
Feb 17AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Jan 08
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
Dec 02AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Nov 18AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
May 16
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
Apr 25AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
Apr 09Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.1% | 1.2% | -0.6% |
| 1Y | 10.8% | 28.8% | 15.5% |
Return vs Industry: ABBV underperformed the US Biotechs industry which returned 28.8% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABBV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | US$410.36b |
| Earnings (TTM) | US$4.19b |
| Revenue (TTM) | US$61.16b |
Is ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$61.16b |
| Cost of Revenue | US$17.36b |
| Gross Profit | US$43.80b |
| Other Expenses | US$39.62b |
| Earnings | US$4.19b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.37 |
| Gross Margin | 71.62% |
| Net Profit Margin | 6.84% |
| Debt/Equity Ratio | -2,090.3% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Apr 15 2026 |
| Dividend Pay Date | May 15 2026 |
| Days until Ex dividend | 43 days |
| Days until Dividend pay date | 73 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/02 00:12 |
| End of Day Share Price | 2026/03/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 49 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |